AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia

Grant

Date/time Interval

  • November 4, 2016 - November 3, 2024
  • Total Award Amount

  • 18500.00
  • Direct Costs

  • 14683.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Jeanine Dumas   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator